CNS Pharmaceuticals
CNSP
12 hedge funds and large institutions have $349K invested in CNS Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 → 12 (+2)
3.44% more ownership
Funds ownership: 20.03% → 23.47% (+3.4%)
47% less capital invested
Capital invested by funds: $652K → $349K (-$304K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$96.1K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$50.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.43K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$489 |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$81K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$21 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
1
Stonepine Capital Management
Bend,
Oregon
| $146K | +$50.4K | +12,173 | +25% |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $110K | – | – | – |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $55.7K | +$96.1K | +23,189 | New |
|
|
BFM
4
Boothbay Fund Management
New York
| $32.3K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.13K | +$5.43K | +1,310 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $1.74K | +$489 | +118 | +19% |
|
|
SIS
7
Sound Income Strategies
Ft Lauderdale,
Florida
| $36 | – | – | – |
|
|
BC
8
Barrett & Company
Providence,
Rhode Island
| $19 | – | – | – |
|
|
MCM
9
MAI Capital Management
Independence,
Ohio
| $8 | – | – | – |
|
|
DB
10
Danske Bank
Copenhagen K,
Denmark
| $2 | – | – | – |
|
|
CIAM
11
Caitong International Asset Management
Hong Kong
| $2 | +$4 | +1 | New |
|
12
Citigroup
New York
| $2 | +$4 | +1 | New |
|
|
DS
13
DRW Securities
Chicago,
Illinois
| – | -$81K | -15,429 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$21 | -4 | Closed |
|
CNSP Hedge Fund Activity: Q1 2026 in Review
12 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q1 2026, worth a combined $349K — down 47% from $652K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNSP positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $96.1K. The largest seller was DRW Securities, exiting entirely with an estimated $81K sold.
- 12 institutional investors held CNS Pharmaceuticals (CNSP) as of Q1 2026, up from 10 in Q4 2025.
- Funds reported $349K of CNS Pharmaceuticals stock for Q1 2026, down 47% quarter-over-quarter.
- 4 funds opened new CNS Pharmaceuticals positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest CNS Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $96.1K added.
- The largest CNS Pharmaceuticals seller in Q1 2026 was DRW Securities, an estimated $81K sold.
Based on aggregated 13F filings for Q1 2026.